ImmuCell Corporation (ICCC): Price and Financial Metrics


ImmuCell Corporation (ICCC): $9.65

0.44 (+4.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICCC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

ICCC POWR Grades


  • Growth is the dimension where ICCC ranks best; there it ranks ahead of 0% of US stocks.
  • 500 - Internal server error
  • ICCC's current lowest rank is in the Growth metric (where it is better than 0% of US stocks).

ICCC Stock Summary

  • With a market capitalization of $66,503,900, Immucell Corp has a greater market value than just 12.69% of US stocks.
  • With a one year PEG ratio of 350.67, Immucell Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.45% of US stocks.
  • Price to trailing twelve month operating cash flow for ICCC is currently 50.55, higher than 91.82% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Immucell Corp are UAMY, JBSS, OXBR, CPIX, and INTT.
  • ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to immucell.com.

ICCC Price Target

For more insight on analysts targets of ICCC, see our ICCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.5 (Moderate Buy)

ICCC Stock Price Chart Interactive Chart >

Price chart for ICCC

ICCC Price/Volume Stats

Current price $9.65 52-week high $13.20
Prev. close $9.21 52-week low $3.80
Day low $9.10 Volume 17,900
Day high $9.91 Avg. volume 39,948
50-day MA $9.90 Dividend yield N/A
200-day MA $7.43 Market Cap 74.65M

ImmuCell Corporation (ICCC) Company Bio


ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.


ICCC Latest News Stream


Event/Time News Detail
Loading, please wait...

ICCC Latest Social Stream


Loading social stream, please wait...

View Full ICCC Social Stream

Latest ICCC News From Around the Web

Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.

ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021

PORTLAND, Maine, May 13, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2021. Product Sales Results: Total product sales decreased by 16%, or $803,000, to $4.1 million during the three-month period ended March 31, 2021 versus the comparable period during 2020.Total product sales increased by 2%, or $316,000, to $14.5 million during the twelve-month period ended March 31, 2021 versus the twelve-month period ended March 31, 2020. Management’s Discussion:“Demand was higher than we could...

Yahoo | May 13, 2021

ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021

Conference Call Scheduled for Friday, May 14, 2021 at 9:00 AM ETPORTLAND, Maine, May 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2021 after the market closes on Thursday, May 13, 2021. The Company has scheduled a conference call the next morning, Friday, May 14, 2021, at 9:00 AM ET to review the results as well as its recent equity raise. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A tel...

Yahoo | May 6, 2021

ImmuCell Closes $4,250,000 Equity Financing

PORTLAND, Maine, April 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has closed an equity investment. On April 14, 2021, the Company issued the aggregate of 515,156 common shares at $8.25 per share directly to its largest stockholder (the Pessin family) and several other investors, raising gross proceeds of $4,250,037, with minimal closing costs. These shares have been registered under the Company’s effective shelf registration statement on Form S-3. “This funding enables us to move forward aggressively with several critical investme...

Yahoo | April 14, 2021

The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) I...

Benzinga | January 28, 2021

ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020

PORTLAND, Maine, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company…

GlobeNewswire | January 7, 2021

Read More 'ICCC' Stories Here

ICCC Price Returns

1-mo 3.88%
3-mo -11.63%
6-mo 71.71%
1-year 130.86%
3-year 25.98%
5-year 50.55%
YTD 62.18%
2020 15.53%
2019 -26.95%
2018 -19.80%
2017 47.73%
2016 N/A

Continue Researching ICCC

Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:

Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7308 seconds.